Clinical Trial Update: Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures [Phase 2]

View source ↗

Summary

Phase 2 trial update on BGG492 as adjunctive treatment for partial onset seizures reports efficacy and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• BGG492

Snippet

Sponsor: Novartis | Conditions: Partial Onset Seizures | Phase 2 | Status: COMPLETED